Skip to main content
. 2012 Apr 22;2012:479348. doi: 10.1155/2012/479348

Figure 3.

Figure 3

Effects of chronic ALD on proceramide pathway activation in liver. Using a fluorogenic assay, (a) neutral, (b) acid, and (c) alkaline sphingomyelinase activities were measured in homogenates of liver from control or chronic ALD subjects. Hepatic ceramide profiles were measured in lipid extracts by LC/MS/MS. (d) CerC14:0, (e) CerC16:0, (f) CerC18:0, (g) CerC20:0, and (h) CerC24:0 levels are expressed as pg/mg protein. (i) Total ceramide immunoreactivity was measured by direct-binding ELISA. Intergroup comparisons were made using Student's t-tests and significant P values are shown over the graphs.